The GSK Oncology pipeline is entering a high-velocity phase of data delivery, with over 30 abstracts accepted for presentation at this year’s most influential medical congresses. By focusing on immuno-oncology and tumor-cell targeting, the company is moving beyond just “treating” cancer to aiming for durable, long-term remission. This year’s data sets are particularly significant as they provide real-world evidence of how these therapies perform over several years, rather than just months.
At the core of this progress is a commitment to precision medicine, ensuring the right treatment reaches the right patient at the optimal time. The GSK Oncology pipeline is designed to address the mechanisms of resistance that often cause treatments to fail, utilizing platforms like Antibody-Drug Conjugates (ADCs) and next-generation small molecules to stay one step ahead of the disease.
The presentations will feature updated results for Blenrep (belantamab mafodotin) in multiple myeloma, which continues to show promise in late-stage trials. These findings suggest that by targeting BCMA (B-cell maturation antigen), the pipeline can offer a potent alternative for patients who have exhausted other lines of therapy.
In the realm of solid tumors, Jemperli (dostarlimab) remains a standout asset within the GSK Oncology pipeline. Recent modeling data to be presented at ASCO suggests that for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer, the combination of Jemperli and chemotherapy could potentially lead to a cure. This shift from palliative management to curative intent marks a watershed moment for gynecologic oncology.
Expanding the GIST and Myelofibrosis Frontiers
Beyond its established leaders, the GSK Oncology pipeline is rapidly diversifying into gastrointestinal stromal tumors (GIST). The company is set to share Phase Ib data for velzatinib (IDRX-42), a highly selective inhibitor of KIT mutations. The encouraging activity seen across multiple KIT variants has allowed GSK to fast-track the Phase III StrateGIST trial, aiming to provide a more robust first-line option for patients who currently face high rates of resistance to standard care.
In hematology, the pipeline also highlights Ojjaara/Omjjara (momelotinib) for myelofibrosis. New analyses from the SIMPLIFY-1 and SIMPLIFY-2 trials demonstrate that patients can transition from other JAK inhibitors to momelotinib without a loss of symptom control. This is a critical development for patients suffering from anemia, a common complication that often limits the use of traditional myelofibrosis treatments.
For those tracking the broader scientific impact of these clinical trials, you can find detailed abstracts on the ASCO Annual Meeting Portal or the EHA Congress Library. These external resources provide DoFollow links to the peer-reviewed data sets that inform current clinical guidelines.
GSK Oncology Pipeline
| Therapy Name | Target Mechanism | Primary Indication | Trial / Milestone |
| Blenrep | BCMA ADC | Multiple Myeloma | DREAMM-7 & 8 (Long-term) |
| Jemperli | PD-1 Inhibitor | Endometrial Cancer | RUBY Trial (Curative modeling) |
| Velzatinib | KIT Inhibitor | Advanced GIST | Phase III StrateGIST Initiation |
| Ojjaara | JAK1/2, ACVR1 | Myelofibrosis | SIMPLIFY 1 & 2 (Switching data) |
| Strategic Focus Area | Platform Technology | Conference | Clinical Stage |
| Hematology | BCMA-Targeting ADC | EHA 2026 | Phase III / Marketed |
| Immuno-Oncology | Monoclonal Antibody | ASCO 2026 | Phase III / Marketed |
| Solid Tumors | Selective Small Molecule | ASCO 2026 | Phase III (Accelerated) |
| Myeloid Diseases | Multikinase Inhibitor | EHA 2026 | Post-Marketing / Phase III |
